Holen Sie sich die Stockscreener-App
7.75
6.51%
-0.54
Handel nachbörslich:
7.75
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
[Form 4] Emergent BioSolutions Inc. Insider Trading Activity - Stock Titan
Emergent BioSolutions (EBS) SVP has 694 shares withheld for RSU taxes - Stock Titan
Emergent BioSolutions (EBS) EVP uses 2,018 shares to cover RSU taxes - Stock Titan
Emergent BioSolutions (EBS) SVP reports 1,741-share tax withholding on RSU vesting - Stock Titan
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions: Down 40%+ From Recent Highs And Likely More To Come (NYSE:EBS) - Seeking Alpha
U.S. – Johnson & Johnson in charge of Baltimore vaccine facility - Digital Journal
Emergent BioSolutions Supports Victoria’s Voice Foundation’s National Naloxone Awareness Day to Help Save Lives from Opioid Overdose - The Manila Times
Emergent (EBS) Q1 2026 Earnings Transcript - AOL.com
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Emergent Biosolutions (EBS) and Compass Therapeutics (CMPX) - The Globe and Mail
Emergent BioSolutions (EBS) Consolidates Near Key Support After Flat SessionJurik MA - thelegaladvocate.com
Emergent BioSolutions (EBS) Secures $64.5M Contract Modification - GuruFocus
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G)(Equine)] to Support U.S. Biodefense Strategy - The Manila Times
Emergent BioSolutions receives $64.5 million contract modification for BAT® to support U.S. biodefense strategy - marketscreener.com
Emergent Biosolutions Receives $64.5 Million Contract Modification For Bat® To Support U.S. Biodefense Strategy - TradingView
Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT® [Botulism Antitoxin ... - Caledonian Record
U.S. health agency awards $64.5M botulism antitoxin deal to Emergent - Stock Titan
EBS Technical Analysis | Trend, Signals & Chart Patterns | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
EBS Stock Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - Insider Monkey
Emergent BioSolutions to Participate in Upcoming Investor Conferences - The Manila Times
Emergent BioSolutions execs line up Goldman Sachs, Jefferies investor talks - Stock Titan
Emergent Biosolutions donates thousands of NARCAN Nasal Spray units across the U.S. since 2021 - Traders Union
Emergent BioSolutions (EBS) Secures ACAM2000 Approval in Saudi A - GuruFocus
Emergent BioSolutions Receives Saudi Food and Drug Authority Approval for ACAM2000® [Smallpox and Mpox (Vaccinia) Vaccine, Live] - marketscreener.com
Saudi Arabia approves smallpox and mpox vaccine for people at high risk - Stock Titan
Emergent BioSolutions Inc. Common Stock (NYSE:EBS) Stock Quote - The Chronicle-Journal
Global governments turn to Emergent Biosolutions for crisis health preparedness - Traders Union
EBS Stock Price, Quote & Chart | EMERGENT BIOSOLUTIONS INC (NYSE:EBS) - ChartMill
Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Common Stock (NY: EBS - FinancialContent
SABS: SAB-142 progresses in phase II-B with robust funding and regulatory clarity, targeting type 1 diabetes - TradingView
EBS SEC FilingsEmergent Biosolutions Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Emergent outlines $170M-$185M Q2 revenue outlook while maintaining $720M-$760M 2026 revenue guidance - MSN
Emergent BioSolutions Inc. (EBS): Investor Outlook with a Promising 31.43% Potential Upside - DirectorsTalk Interviews
Tranche Update on Emergent BioSolutions Inc.'s Equity Buyback Plan announced on May 7, 2025. - marketscreener.com
Travel Vaccines Market Size is Projected to Reach US$ 5,914.22 - openPR.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Harsanyi Zsolt - Moomoo
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
MSN Money - MSN
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Fowler Neal Franklin - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Zoon Kathryn C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Richard Ronald - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director FOWLER JOHN D JR - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director White Marvin L - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director DeGolyer Donald W - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Director Dayal Sujata Tyagi - Moomoo
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director Dayal sells $115,610 in stock By Investing.com - Investing.com South Africa
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):